---
categories: 
- Database
- Release
date: 2021-05-06
title: Database release
github_url: https://github.com/vanallenlab/moalmanac-db/releases/tag/v.2021-05-06
---
The following changes were made to the Molecular Oncology Almanac in this release - 

Added entries:
- (FDA) _ERBB2_ amplifications and sensitivity to pembrolizumab in combination with fluoropyrimidine, trastuzumab, and platinum-based chemotherapy in gastric or gastroesophageal junction adenocarcinoma.
- (Inferential) _CD274_ amplifications and sensitivity to pembrolizumab in gastric or gastroesophageal junction adenocarcinoma.

Edited entries:
- (Clinical evidence) _NF1_ germline variants associated with radiation therapy was not labeled with a clinical assertion. "1" has been set for adverse_event_risk.
- (Inferential) _ERBB2_ amplification and sensitivity to trastuzumab was changed to an inferential assertion from FDA. The description was also updated for these entries.